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ABSTRACT 
 
O’HERN, PATRICK    From Gene to Behavior: Investigation of Ppt1 and Ppt2 RNAi 
induced knock-down during Drosophila Neurogenesis, June 2011. 
 
ADVISOR: Quynh Chu-LaGraff 
 
 
 Infantile Neuronal Ceroid Lipofuscinosis (INCL) is caused by a mutation of the 
gene CLN1, which encodes palmitoyl protein thioesterase 1 (PPT1). PPT1 is a lysosomal 
enzyme that cleaves the thioester bond connecting long chain fatty acids of palmitoylated 
proteins. Without PPT1, palmitoylated proteins are not degraded properly and this causes 
unwanted build up in neurons leading to fatality. Recently, it has been thought that a 
mutation in a similar enzyme, palmitoyl-protein thioesterase 2 (PPT2), another lysosomal 
hydrolase, may also be responsible for INCL by causing a similar effect of Ppt1 
deficiency. A bioinformatics analysis in this study showed similarities between human 
PPT1/PPT2 and Drosophila Ppt1/Ppt2.  Therefore, using Drosophila melanogaster as a 
model, the role of Ppt1 and Ppt2 can be elucidated using the molecular genetic technique 
RNA interference (RNAi). RNAi targets the mRNA for destruction thus creating a 
mutant phenotype. In this study, knock-down of Ppt1 and Ppt2 mRNA expression was 
achieved using the Gal4-AUS system.  Transgenic Ppt1-UAS and Ppt2-UAS fly lines 
were crossed into various Gal4 driver lines specific for different subsets of embryonic 
CNS neurons. Embryos from these crosses were immunohistochemically stained with 
FAS II antibody and stage 16 embryos were examined for neural defects. Preliminary 
results indicate that Ppt1 and Ppt2 RNAi knock-down disrupted nervous system 
development in Drosophila. Furthermore, mutant embryos were allowed to progress to a 
larval state where motor studies showed differences in locomotor ability. These results 
provide insights into the mechanism of Ppt1 and Ppt2 in causing INCL pathology.  
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INTRODUCTION 
NEURONAL CEROID LIPOFUSCINOSiS  
 Neuronal Cerioid Lipofuscinosis includes a group of rare lysosomal storage 
disorders. It is very rare as it effects only 0.1 to 7 per 100,000 live births each year. NCLs 
are inherited in an autosomal recessive manner meaning that if Mendilian genetics is 
applied it can be assumed that if both parents are carriers one of four children will be 
normal, two of four children will be carriers and one of four children will manifest the 
disease (see Figure 1) (5).  
 
Figure 1: Genetics of autosomal recessive disorders and diseases 
(http://www.discern-genetics.org/images/6.1.gif) 
 
  
 NCLs are grouped into eight different categories: infantile classic NCL, late 
infantile classic NCL, juvenile classic NCL, adult NCL, Finish variant late infantile NCL, 
variant late infantile NCL, variant late infantile NCL, and Northern epilepsy/progressive 
epilepsy with mental retardation (EPMR). Each NCL case is grouped into one of these 
categories based on the gene causing the disorder; so far six genes have been discovered 
that cause human NCL: CLN1, CLN2, CLN3, CLN5, CLN6, CLN8 (17).  Table 1 
outlines the known disorders and their corresponding genetic location and products. 
  
 
Table 1: A summary of the different genes involved in NCL along 
with the clinical disorders, chromosomal loci and gene products 
(19).  
 
  
 Currently, diagnosing these disorders is difficult given their overlapping 
pathology. The first sign of any NCL is generally retinal degeneration and 
ophthalmologists are generally the first to notice the loss of cells in the retina. From here, 
patients with a suspected NCL disorder undergo blood tests, skin sampling, brain scans, 
and electroencephalograms to confirm (16). Furthermore, genetic screening has recently 
become available for those NCLs that have been cloned (13). The present study shows, 
however, that it is possible other genes than those identified by the current literature may 
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be involved in NCLs. Presently, there is no treatment for any of the disorders other than 
symptomatic treatment (9).  
 
INFANTILE NEURONAL CEROID LIPOFUSCINOSIS (INCL)  
 INCL is responsible for 20% to 25% of all NCL cases. The symptoms generally 
become apparent around six months of age and include retarded head growth, low muscle 
tone, and hyperexcitability. This condition is progressive and as age increases, patients 
typically experience cognitive dysfunction, blindness, loss of motor skills, and seizures. 
The average lifespan of an INCL patient is between 6 and 13 years (9).  
 INCL is caused by a mutation of the CLN1 gene, which encodes palmitoyl protein 
thioesterase 1 (PPT1). PPT1 is a lysosomal enzyme responsible for cleaving the thioester 
bond that connects long chain fatty acids of palmitoylated proteins (15). The most 
common fatty acid cleaved by the actions of PPT1 is palmitate. The active site of PPT1 
includes a catalytic triad made up of: aspartate (Asp233), histidine (His289) and serine 
(Ser115) (1).  
 The CLN1 gene has a chromosomal location of 1p32 and 9 exons. In INCL cases, 
there have been 40 different mutation locations within CLN1 that have been identified in 
INCL patients. The various mutations are as follows: 19 missence mutations that alter 
amino acid residues, 9 nonsense mutations that delete HIS289 (the histidine of the active 
site) and cause a loss of enzymatic activity, 9 small deletions or insertions, and 3 
mutations in splice sites which decrease enzymatic activity due to resulting geometric 
changes in the PPT1 active site (13).  
 Without PPT1, the palmitoylated proteins are never degraded and build up in the 
cell. This build up is thought to be the cause for the neurodegeneration seen in INCL 
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patients (5). Interestingly, while the build up of storage material occurs in cells 
ubiquitously, the only detrimental effects occur in neural cells (1). Therefore, there must 
be a process or component specific to neural cells that is disrupted by the accumulation of 
storage material. Unfortunately, current research has not shown exactly what this 
necessary factor is and it remains one of the large mysteries of this disorder (11). 
 CLN1 also encodes Ppt2, another gene responsible for catalyzing the hydrolysis 
of long chain fatty acyl CoAs and preventing unwanted build up of storage materials 
within the cell. Despite their similarities in function, Ppt2 only shares an 18% identity to 
Ppt1 and they are thought to perform non-redundant roles (see Figure 2) (21). 
Furthermore, in an experiment with Ppt1 and Ppt2 knock-out mice, the Ppt1 mice 
experienced more severe NCL-like symptoms than the Ppt2 mice. This suggests that Ppt2 
serves a separate role than Ppt1, but nevertheless causes the same kind of autofluorescent 
storage material buildup characteristic of INCL (10). 
 
 
Figure 2: A PPT1 and PPT sequence comparison. Black sections represent 
identical residues and gray represents conserved substitutions (2).   
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 The undegraded proteins that result from Ppt1 mutation and Ppt2 mutation may 
are better known as granular osmiophillic deposits (GRODs). Despite the fact that these 
GRODs are expressed ubiquitously throughout the human body, it is only the nervous 
system that appears to be affected. The build up of GRODs in neural cells can trigger the 
apoptosis of the central nervous system, which is responsible for the symptoms and 
prognosis of INCL (16).  
 Recent findings have shed some light on how GRODs cause apoptosis of neural 
cells. GRODs are made up of saposins A and D and build up in the endoplasmic 
reticulum. The stress on the cell can cause the unfolded protein response (UPR) pathway 
initiated by the cell in order to restore homeostasis. This pathway can activate caspase -
12 which in turn can activate caspase-3 leading to programmed cell death of the nervous 
system in INCL patients (23).  
 
DROSOPHILA MELANOGASTER AS A MODEL ORGANISM 
 The model organism used in this research project was Drosophila melanogaster. 
It is useful and effective for examining neurodegenerative diseases due to its short life 
span, easy maintainability, sequenced genome, complex brain and involved nervous 
system (7). Over 100 years of research has been conducted with the fruit fly and 
researchers have discovered over 70% of the genetic loci for human diseases have a 
conserved ortholog in Drosophila. Therefore, the fruit fly is a very useful model 
organism for the investigation of human diseases, such as Batten Disease (8).  
 Drosophila express a PPT1-like gene, called Ppt1, that is 55% identical and 72% 
similar to that seen in humans. The sequence alignment of fly Ppt1 alongside human 
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PPT1 can be seen in Figure 2. The black areas are where the alignments are identical and 
the white is where they are different (8).  
 
QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.
 
 
 
 
 
 
 Figure 3: A sequence alignment of human, bovine, mouse and fly Ppt1 (8). 
    
 Ppt1 is also functionally identical in that it cleaves the same substrate as its human 
ortholog. It is also identical at the biochemical level seeing as the Drosophila form of 
Ppt1 contains the conserved serine-aspartate-histidine catalytic triad necessary for 
enzymatic activity. This catalytic triad is a structurally identical active site shared 
between Ppt1 and PPT1 (see Figure 3) (1). These similarities make it possible to 
accurately model INCL within Drosophila.   
 
        Figure 4: The conserved serine-aspartate-histidine catalytic triad (1).  
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 Previous researchers have investigated many different mutations in order to model 
INCL in Drosophila, the first of which being the deletion of the gene coding for Ppt1 and 
three neighboring genes. Unfortunately, model organisms are typically unable to model 
disease flawlessly. This is true for Drosophila as well, however, Ppt1 deficient flies do 
exhibit the accumulation of autofluorescent storage materials (3). This material seems to 
differ in composition to the human GRODs and were actually more similar in 
biochemical make-up to the build-up found in human Tay-Sachs and Sandhoff diseases, 
two other lysosomal storage disorders (12). In addition, flies lacking Ppt1 do not 
experience neurodegeneration, but have a shorter lifespan than wild type flies (3).  
 There has been less research done on Ppt2, but the fly ortholog is 40% identical 
and 57% similar to the PPT2 gene seen in humans. Additionally, PPT2 shares a 26% 
identity with PPT1 and as said before, they have an 18% amino acid homology. A similar 
conserved catalytic triad in PPT1 is also seen in PPT2, which accounts for its similarity in 
function (see Figure 4) (2).  
 
 
 
 
 
 
 
 
 
 
QuickTime™ and a
Figure 5: An electron density map of the PPT2 conserved serine-aspartate-
histidine catalytic triad using crystallography NMR software (2). 
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 Unfortunately, the crystal structures of Drosophila Ppt1 and Ppt2 have not been 
thoroughly compared to the human forms. Therefore, there is a need to investigate the 
possible similarities in order to ensure that it would be possible to model the disorder if 
flies.  
 
RNA INTERFERENCE IN THIS INVESTIGATION 
 In previous research studies on Ppt1 with Drosophila, researchers have 
investigated the effects of gene knock-out of Ppt1 and single point mutations of Ppt1. 
Gene knock-out involves the removal of an entire portion of DNA from the Drosophila 
genome, which prevents the production of any Ppt1 protein. The disadvantage in 
modeling the disease in this manner is the impossibility to remove solely the portion of 
DNA coding for Ppt1 and therefore other genes were silenced as well. A single point 
mutation entails the alteration of a single nucleotide within the segment of DNA that 
encodes Ppt1. This mutation did not completely silence Ppt1 gene expression, but 
produced a less effective form of Ppt1 (3). 
 In terms of Ppt2, investigators have looked at the phenotype of Ppt2 knock out in 
mice, but this has never before been performed in Drosophila. While the disease 
characteristics of the PPT2 knock-out mice were not as severe as the PPT1 knock-out 
mice, the presence of autofluorescent storage material was still present. The researchers 
in this study concluded, however, that PPT2 must serve a separate role as PPT1 (10). In 
terms of Drosophila research, there remains a large amount of ground to be covered both 
in terms of knock-out and knock-down with PPT2.  
 In this research project, the effects of gene knock-down of Ppt1 and Ppt2 using 
RNA interference (RNAi) was investigated. RNAi is a technique for halting mRNA from 
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making proteins and is 75% to 90% effective for the Ppt1 gene in Drosophila. It is 
superior to the two aforementioned techniques because it can more accurately hinder  
Ppt1 and Ppt2 expression. Furthermore, this knock-down can be achieved in a tissue-
specific manner allowing researchers to specifically target a tissue. In the present study, 
RNAi was conducted specifically in neural tissues and therefore, all other cell types had 
both Ppt1 and Ppt2 present (19).  
 RNAi involves the production of a long double stranded RNA (dsRNA) that 
travels into the cytoplasm of cells. A protein complex, called Dicer, recognizes dsRNA 
and degrades it into small interfering RNA (siRNA) about 20 nucleotides long. One of 
the two strands of the siRNA is the guide strand complementary to the mRNA coding for 
Ppt1.The other strand is the passenger strand. Argonaute, a complex of catalytic proteins, 
binds to siRNA forming what is referred to as the RNA-induced silencing complex 
(RISC). RISC cleaves off the passenger strand from the dsRNA, binds to the complement 
target mRNA coding for Ppt1 or Ppt2 and degrades it, ultimately hindering Ppt1 or Ppt2 
production (19).  
 
GAL4-UAS SYSTEM  
 In order to initiate RNAi, a gene within the fly genome needed to be activated that 
produced a dsRNA containing segments complementary to the Ppt1 and Ppt2 mRNA. 
This gene was activated using the GAL4-UAS system in which two transgenic fly lines 
were designed and utilized. The first line is the UAS-Ppt1 transgene fly, in which the 
transgene coding for the Ppt1 or Ppt2 dsRNA is placed downstream of a UAS activation 
domain that consists of GAL4 binding sites. GAL4 is essentially an activator, the absence 
of GAL4 renders the transgene coding for dsRNA inactive in the UAS-Ppt1 and UAS-
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Ppt2 flies. In order to activate the gene, the UAS-Ppt1 and UAS-Ppt2 flies were crossed 
with Enhancer-trap GAL4 flies. Therefore, the progeny of the cross expressed the target 
transgene encoding the dsRNA necessary for RNAi (see Figure 6) (6).  
Tissue-specific 
expression of Gal4 
Homozygous UAS-Ppt1 or 
Ppt2 transgene fly 
Homozygous Enhancer-trap 
Gal4 fly 
Tissue-specific transcriptional 
activation of Ppt1 or Ppt2 
transgene 
 
 
Figure 6: Illustration of the UAS-Gal4 system with labelled parent flies as 
well as a depiction of the effects of how the RNAi transgene for either 
Ppt1 or Ppt2 is activated in the progeny (18).  
 
 
AIM OF INVESTIGATION 
 The purpose of this study was to investigate whether or not Ppt1 and Ppt2 RNAi 
knock-down had an effect during Drosophila neural development and on larval motor 
ability. First, a bioinformatics study was completed in order to investigate structural 
similarities between human PPT1, human PPT2, Drosophila Ppt1 and Drosophila Ppt2. 
This examination involved the compilation of PPT1 and PPT2 published crystal 
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structures as well as FASTA amino acid sequences for all four proteins. These sequences 
were then threaded into the crystal structures using the computer program DeepView / 
Swiss-pdb Viewer (4). This allowed us to visualize the structural similarities between the 
fly and human versions of these genes to further support our evaluation of PPT1 and 
PPT2 as having a useful ortholog in flies and it potentially playing a role in INCL. 
 The following fly crosses were used to investigate the effects of Ppt1 RNAi 
induced knock-down on CNS development: 5499x8760, 25952x8760, 5499x7470, and 
5499x7466. 5499 and 25952 are UAS-Ppt1 transgene flies while 8760, 7470 and 7466 
are the Enhancer-trap Gal4 flies. For Ppt2 RNAi induced knock-down, the crosses used 
are as follows: 1458x8760, 1459x8760. 1459 and 1458 are UAS-Ppt2 transgene flies and 
again, 8760 carried the Enhancer-trap GAL4 information. The fly crosses were created 
using female virgin flies from one strain and male flies from the other. Embryos of the F1 
generation were collected, stained with FasII and examined with a SPOT color CCD 
camera.  
 Each stage 16 well-stained embryo was observed and compared to wild type 
embryos at stage 16. Furthermore, as an extra control, embryos were compared to those 
collected from each parent fly strain. In this investigation, the main component viewed 
was the central nervous system. Fas II staining of the central nervous system is expressed 
in three discrete subsets of axons that run the entire length of the embryo during late 
neurogenesis as seen in Figure 4 (3). Abnormal embryos were identified by 
discontinuities, disorganization, or scalloped appearance in these three subsets of axons. 
After the embryos were observed, the numbers of abnormal embryos and normal 
embryos were tallied and percentages were calculated for each cross. Abnormal embryos 
for Ppt1 deficiency were also classified into four groups based on severity: extremely 
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mild, mild, severe, and extremely severe. The various effects of RNAi from specimen to 
specimen determined this degree of severity.   
 
      Figure 7: A Drosophila wild type central nervous system as visualized by a FasII    
staining. 
 
 Beyond staining embryos, motor ability of mutant larvae was evaluated in order 
to further correlate the fly phenotype to the human phenotype. As stated before, motor 
problems are seen in humans and motor differences in Ppt1 or Ppt2 knock-down larvae 
would further support that these flies are successful model organisms for this experiment. 
In order to access motor ability, mutant and wild type larvae were subjected to two motor 
assessments. The techniques in this study have been used previously by researchers to 
investigate the behavioral locomotion in Drosophila larvae carrying the yellow gene. 
This gene causes pigmentation and locomotion problems in Drosophila (14).  The 
technique involves watching larvae transverse across an agar plate, while keeping track 
of how far they travel in a two minute period and how many lateral bending motions they 
make during this period. These locomotor characteristics tell us how many turns the 
larvae made (lateral bending) and how fast the larvae are able to move (distance 
traveled).  
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EXPERIMENTAL METHODS 
 
PROTOCOL FOR BIOINFORMATICS IN DEEPVIEWER / SWISS PDB (4) 
 Crystal structure data for PPT1 and PPT2 from PDB.org was downloaded in a 
pdb.txt format. The FASTA amino acid sequences were then found and downloaded for 
PPT1, PPT2, Ppt1 and Ppt2 from uni-prot.org. The crystal structure for both PPT1 and 
PPT2 was opened in Deepviewer and various protein FASTA sequences were threaded 
through the crystal structures:  
1. Ppt1 (Pubmed #Q9W3C7)was threaded through PPT1 (PDB #3GRO) 
2. Ppt2 (Pubmed #Q9VKH6) was threaded through PPT2 (PDB #3PJA) 
3. PPT2 (Pubmed #Q9UMR5) was threaded through PPT1 (PDB #3GRO)  
 The threading was completed using the following program within the Swiss PDB 
program:  
1) Choose Alignment from the Windows tab in the toolbar at the top 
2) A separate window should appear. Click on the very first line that indicates the 
pKa of the molecule. It should turn red.  
3) In the Fit toolbar at the top, choose Magic Fit. After this is done, choose 
Improved Fit from the same toolbar. This will optimize the alignment.  
4) In the Color toolbar, choose Color By Alignment Diversity. 
5) In the Swiss Model toobar choose Update Threading Now, unless Update 
Threading Display Automatically is already chosen.  
6) Click on the little arrow located to the right of the question mark of the alignment 
window. The window should expand and show a curve that shows the energy of 
the residue. The residue is stable when it’s energy is below zero.  
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7) Click on the Smooth text in the window and change the smoothing factor to 1. 
This means that the energy of each residue will be the average of the energy itself 
and the energy of 1 flanking residue on each side.  
8) In the Swiss Model toolbar, choose Auto Color By Threading Energy to better 
visualize the potential energy of each structure.  
9) Click on the E=XX text in the alignment window to re-compute the energy for the 
model.  
10) Click the Select toolbar, choose Residues Making Clashes to stabilize the model. 
This can be done multiple times to adjust the model.   
 
EMBRYO COLLECTION, STAINING, AND IMAGING  
 Fly strains were kept at a constant temperature of 25°C with standard fly food 
(recipe below). The fly strains came from the Vienna Fly Stock Center and included 
5499, 25952, 7470, 7466, 8760, 1458 and 1459. Flies from each individual mutant strain 
were transferred to collection bottles with molasses/yeast caps (recipe below). The female 
flies laid their embryos on the molasses/yeast caps overnight. Every 24 hours, these 
plates were changed and embryos were washed off onto a filter. The filter along with the 
embryos was placed into bleach for five minutes. All embryos were then placed in a 
1.5mL microfuge tube with 500 uL FIX solution (450uL PEM and 50uL 37% 
formaldehyde) and 500uL heptane for 20min at room temperature. During this time, the 
microfuge tubes were agitated vigorously on the vortex to remove the vitelline 
membranes. The FIX solution was removed and the embryos were placed in methanol 
and agitated for 30 seconds to separate the interphase material. The heptane, methanol, 
and material in interphase were removed leaving only the devitellinized embryos at the 
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bottom of the microfuge tube.  The embryos were then washed three times in methanol 
and preserved at -20’C.  
Fly Food  
12 g agar 
44 g yeast 
105 g cornmeal  
700 mL H20  
Boil for 10 minutes  
Add 750 mL H20 
Cool to 65°C 
Add 10 mL 30% Tegosept and 10 mL propinoic acid  
Mix for 5 minutes, pour into containers, cap containers once food is hardened  
Store food in the 4°C 
 
Molasses plates  
4 g agar 
6 mL molasses  
100 mL H20 
Microwave until agar dissolves  
Pour into Petri dish caps, allow to harden  
Store in 4°C 
 
 50uL of embryos stored in methanol at 20’C were re-hydrated in 0.1% PBT 
(500mL Phosphate buffered saline solution and 1mL Triton X-100) in a 1.5mL microfuge 
tube. Embryos were washed in 1mL PBT for 30min, rocking at room temperature. 
Diluted Normal Goat Serum (NGS) (1mL PBT and 50 uL NGS) was then added to the 
embryos for 30 minutes, rocking at room temperature. The primary antibody, FAS II, was 
diluted at 1:5 (75uL antibody and 375uL PBT) and added to the embryos. The embryos 
were then incubated, rocking overnight at 4’C.  
 The next day, the primary antibody was removed and embryos were rinsed 3 
times in PBT. The embryos were washed for 1 hour in PBT, changing solutions every 15 
minutes. The secondary antibody (GαM-HRP) was diluted at 1:250 using PBT. The 
secondary antibody was added to the samples and incubated for 1 hour at room 
     15
temperature. The secondary antibody was removed and the samples were rinsed 3 times 
in PBT. The tissues were washed for 1 hour in PBT, changing solutions every 30 
minutes. After the final wash, all PBT was removed and 300uL premade DAB and 30uL 
hydrogen peroxide (diluted previously to 1:100) was added. The reaction was observed 
under a microscope and it continued until the embryos turned dark brown. Washing the 
embryos with PBT 3 times then stopped the reaction. The embryos were then dehydrated 
by adding 1 mL 50% ethanol for 5 minutes, then 1mL 70% ethanol for five minutes and 
finally 1 mL 100% ethanol overnight.  
 The next day, the ethanol was removed and 700uL of methyl salicylate was 
added. The samples were either stored at 4’C or mounted on slides to view under the 
microscope. All samples and slides were stored at 4’C and in the dark. 
 
FLY CROSSES 
Ppt1 RNAi induced knock-down crosses:  
~ 5499 (Vienna Drosophila RNAi Center: 44Dd/CyO) crossed with 8760 (Bloomington 
Drosophila Stock Center: Gal4-ELAV) 
~ 5499 (Vienna Drosophila RNAi Center: 44Dd/CyO) crossed with 7466 (Bloomington 
Drosophila Stock Center: CQ2-GAL4) 
~ 5499 (Vienna Drosophila RNAi Center: 44Dd/CyO) crossed with 7470 (Bloomington 
Drosophila Stock Center: RN2-GAL4)  
~ 25952 (Vienna Drosophila RNAi Center: TRIP.JF01972) crossed with 8760 
(Bloomington Drosophila Stock Center: Gal4-ELAV) 
 
Ppt2 RNAi induced knock-down crosses:  
 
~ 1458 (Vienna Drosophila RNAi Center: w1118; P{GD399}v1458/TM3) crossed with 
8760 (Bloomington Drosophila Stock Center: Gal4-ELAV) 
~ 1459 (Vienna Drosophila RNAi Center: P{neoFRT}82B P{πM}87E P{πM}97E) 
crossed with 8760 (Bloomington Drosophila Stock Center: Gal4-ELAV) 
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ASSESSMENT OF LARVAE LOCOMOTION  
 Females flies from both the 5499x8760 (Ppt1 RNAi) cross and 2376 (wild type) 
were allowed to oviposit for 24 hours on molasses plates. Behaviors were then scored in 
larvae aged 48, 72, 96, and 120 hours post-hatching.  
 Larval locomotor activity was documented through the use of clear shallow 
rectangular plastic boxes 17 cm in length, 14 cm in width and 2 cm in height filled to a 
depth of 1 cm with 1.5% agar-gel. A grid of 1 cm by 1 cm squares was attached to the 
underside of the box so that it could be viewed from above through the agar and plastic. 
Ppt1 RNAi knock-down flies and wild type flies were transferred individually onto the 
center of the agar surface and the path of each larvae was monitored using an Olympus 
SZ40 stereozoom microscope for two minutes each. The total number of squares crossed 
during this period was recorded. Furthermore, lateral bending of the head and anterior 
segment was also scored for 2 minutes. The amount of larvae tested for both locomotor 
characteristics was 25.  
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RESULTS/DISCUSSION 
 The bioinformatics investigation took a look at three different investigations of 
threading FASTA sequences into crystal structures. First, the Drosophila Ppt1 FASTA 
amino acid sequence was threaded into the human PPT1 crystal structure. This showed 
considerable similarities between the two proteins as indicated by the blue areas of Figure 
13 where the threading was most stable given molecular forces such as Van Der Waals 
forces, hydrophobic interactions, and hydrogen bonding. Next, the Drosophila Ppt2 
FASTA sequence was threaded into the human PPT2 crystal structure. Again, areas of 
the most stabilization are shown in blue, while other colors show differing areas less 
stability with red being the least stable. Finally, the human PPT2 FASTA sequence was 
threaded into the human PPT1 crystal structure showing large areas of structural 
similarity.  
 
 
 
 
 
 
 
 
 
 
Figure 8: Drosophila Ppt1 FASTA information threaded into the PPT1 
Human crystal structure.  
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Figure 9: Drosophila Ppt2 FASTA information threaded into the human 
PPT2 crystal structure.  
 
 
 
 
 
 
 
 
 
Figure 10: Human PPT2 FASTA sequence threaded into the human PPT1 
crystal structure.  
 
 
IMAGES AND ANALYSIS OF DROSOPHILA EMBRYONIC NEUROGENESIS 
 Images of embryos from each cross were taken and saved. All were stage 16 
embryos and stained with FAS II, which is expressed in three discrete axon bundles that 
extend longitudinally down either side of the ventral midline of the embryo. Each cross 
achieved the same purpose, which was to produce the dsRNA required for RNAi of Ppt1 
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production specifically in neural tissue. Thus, they all exhibited the same types of 
phenotypes in the central nervous system, which included discontinuities, thinned and 
thickened axon bundles, and disorganized subsets of axons as seen in the following 
figures. Example of both a wild type and an abnormal central nervous system can be seen 
below in Figures 11 and 12, respectively.  
 
Figure 11: Wild Type embryo stained with FasII. 
 
  
  Figure 12: Abnormal RNAi embryo from 5499 x 8760 cross 
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 Table 1 summarizes the embryo analysis data from each cross. It can be seen in 
this table that each cross exhibited a large number of abnormalities as was expected. The 
normal embryos could have occurred due to contamination within the crosses or could 
have exhibited a phenotype so mild that it was unnoticeably different from wild type. 
This data demonstrates, however, that Ppt1 RNAi knock-down does have an effect during 
neural development.  
 
Fly Strain # of embryos at 
s16 
# w/ 
abnormalities 
% w/ 
abnormalities 
5499 x 8760 81 81 100 
5499 x 7466 67 57 85 
5499 x 7470 106 99 93.4 
25952 x 8760 42 36 85.7 
                       Table 2: Summary of embryo analysis from each cross.  
 
 Figure 13 shows an example of the type of analysis underwent by each embryo 
cross. Not only were embryos in the crosses from Table 2 compared to wild type 
embryos, but they were also compared to embryos from each individual parent strain as a 
control. In Table 3 below, the control data from investigating the progeny of each 
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individual strain supports the assertion that the development of the central nervous 
system was disrupted by RNAi induced knock down of Ppt1.  
 
 
Figure 13: Top image is CNS of 5499x8760 progeny. The middle image is 
of a 8760 only progeny and the bottom image is of a 5499 only progeny.  
 
 
Genotype  % Deefective 
Ppt15499RNAi 0.03 (30) 
Ppt125952RNAi 0 (30) 
Elav-gal4 (8760) 0 (33) 
UAS tauLacZ CQ2-gal4 (7466) 0 (30) 
UAS tauLacZ RN2-gal4 (7470) 0 (35) 
Table 3: Percentage of defective embryos for each parent strain in the 
Gal4-UAS system. Parentheses represent the number of embryos assayed.  
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 An interesting aspect of this data is that a spectrum of severity can be seen 
ranging from extremely mild to extremely severe as seen in Figure 14. This is most likely 
due to the fact that the RNAi technology used to knock-down Ppt1 is 70% - 90% 
effective. 
 
 
 
 
 
 Figure 14: The RNAi spectrum of severity. Ranging from wild type at the top  
 to one of the most severely abnormal phenotypes at the bottom.  
  
 Table 4 summarizes the severity of defects seen in the abnormal embryos of each 
cross. Stage 16 embryos were categorized into four different groups: extremely mild, 
mild, severe, and extremely severe. The classification was based on perceived severity as 
seen in Figures 15-18.  
 It can also be seen that the 5499 x 7470 cross exhibited the most severe phenotype 
which suggests that this cross expresses the most effective form of the UAS-Ppt1 
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transgene as activated by Gal4. This could also mean that this cross is the most effective 
at modeling INCL as it seems to knock-down a larger percentage of Ppt1.  
 
Fly Strain % extremely 
mild 
abnormalities 
% mild 
abnormalities 
% severe 
abnormalities 
% extremely 
severe 
abnormalities 
5499 x 8760 2.5 47 43 7.4 
5499 x 7466 6 31 42 10.4 
5499 x 7470 4.7 33 50.9 9.4 
25952 x 8760 16.6 42.8 31 2.3 
Table 4: Summary of severity of abnormalities seen in the abnormal embryos of each 
cross. 
 
 
      Figure 15: Extremely Mild abnormal embryo from cross 5499 x 7466 
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Figure 16: Mild abnormal embryo from cross 5499 x 7466 
 
 
Figure 17: Severe abnormal embryo from cross 5499 x 7466 
 
 
Figure 18: Extremely severe abnormal embryo from cross 5499 x 7466 
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 Figure 12 shows the abnormal phenotype seen for Ppt2 RNAi knock-down 
embryos. These embryos were also stage 16 and underwent the same protocol as the Ppt1 
knock-down embryos. Furthermore, they exhibited a very similar phenotype with faulty 
axonal  pathfinding in the PNS, disorganized and discontinuous axons in the CNS and 
abnormally thick and thin sections of the CNS (3).  
 
 
 
  
 
 
  
 
 
Figure 19: Abnormal Ppt2 RNAi knock down embryo from 1459x8760 
stained with FAS II antibody.  
 
 
 Table 5 summarizes the embryo analysis data from each cross for the Ppt2 
induced knock-down strains. It can be seen in this table that each cross exhibited 
abnormalities very similar to those seen in Ppt1 RNAi knock down. Again, the normal 
embryos could have occurred due to contamination within the crosses or could have 
exhibited a phenotype so mild that it was unnoticeably different from wild type. This data 
shows, however, that Ppt2 RNAi knock-down has an effect during embryonic 
neurogenesis in Drosophila.  Unfortunately, the embryos from the parent strains are yet 
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to be evaluated and therefore, only the Elav-Gal4 embryo information from the previous 
experiment with Ppt1 was able to act as a control for the data. (see Figure 20).  
 The presence of a phenotype illustrates that Ppt2 is involved in the development 
of the CNS and the lack of this gene results in CNS disruption. Furthermore, the 
observable phenotype seemed to be less severe than Ppt1 RNAi induced knock-down 
indicating that Ppt1 may be more important during CNS development than Ppt2.  
 
Fly Strain # of embryos at 
s16 
# w/ 
abnormalities 
% w/ 
abnormalities 
1459 x 8760 35 32 91.4 
1458 x 7466 10 7 100 
Table 5: Summary of embryo analysis from each Ppt2 knock-down cross.  
 
 
Figure 20: Top image is that of a 1459x8760 CNS. The bottom image is 
the CNS of 8760 progeny.  
 
 
 
     27
LOCOMOTION DATA AND ANALYSIS 
 Figure 21 shows locomotor activity of larvae of the Ppt1 RNAi induced knock-
down strain and wild type strain. Larval locomotion is developmentally related and 
therefore, there are differing amounts of lateral bending for different stages of larval 
development (14). Lateral bending occurrences were similar during 72h or 96h of 
development between the two strains. At 48h and 120h, however, there seemed to be 
significant differences in lateral bending movements where wild type larvae had more 
lateral bending events. Each lateral bend is followed by a change in direction. Thus, it can 
be concluded that at 48h and 120h of development, the Ppt1 knock-down larvae are 
moving in a straighter path as opposed to the wild type larvae which are making more 
turns.  
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Figure 21: Bending behavior for both wild type and Ppt1 knock-down 
larvae at various ages within a 2 minute period. White represents the 
mutant, while grey indicated the wild type strain.  
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 Similarly, the locomotion data that accounted for how far larvae of each strain 
traveled in a two minute period showed that there is not much difference at some stages. 
During the 72h period of development, there was a significant difference in locomotion 
with the mutant strain traveling farther than wild type. Overall, wild type on average 
transversed a shorter distance than Ppt1 knock-down flies.   
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Figure 22: Locomotor activity of wild type and Ppt1 knock-down flies at 
various ages. White represents the mutant strain and black indicated the 
wild type strain. Larval locomotion was measured as a number of squares 
crossed in two minutes.  
 
 As far as drawing conclusions from these two figures, it is difficult to make any 
definitive deductions regarding exactly how the two strains are different, but it can be 
noted that there is an abnormality present in the mutant strain that effects normal 
locomotion. Furthermore, error bars in these two figures were very large compared to 
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previous research with comparable sample sizes. This is most likely due to the larvae 
being born with a 24h collection period from female parent flies. This means that at what 
we perceived to be the 48hr period, there would be larvae that were considerably older. 
The error bars for the mutant strain was noticeably larger than the wild type in Figure 22 
for three of four periods of development, which may be reflective of the ranging severity 
witnessed during the investigation of stained Ppt1 knock-down embryos. Since the data 
points have such variability, it is clear that modifications to the experimental method 
should be made in order to get clearer results.  
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CONCLUSIONS 
 The bioinformatics analysis in the study showed that Ppt1, Ppt2, PPT1, and PPT2 
are structurally similar. This supports previous research that identifies Ppt1 and PPT1 as 
functionally identical and that PPT2 performs a similar function to PPT1 (10). 
Furthermore, the embryonic study in this experiment showed that Ppt1 induced knock-
down results in an abnormal phenotype, which indicates that Ppt1 plays a role in 
embryonic neurogenesis. Similarly, Ppt2 knock-down resulted in a similar phenotype and 
therefore, it may be concluded that it also plays a role in the process of neurogensis. 
These proteins, previously not regarded as developmentally significant, have been shown 
to be important during embryogenesis. In correlation with the human disorder, one may 
deduce that this data provides evidence that INCL patients could exhibit neurological 
pathology in utero.  
 Ppt2 has yet to be investigated on a functional level as compared to PPT2, 
however, their structural similarities suggest that they may be similar in function. 
Furthermore, the FAS II staining procedure in this experiment showed that there are 
likely similarities in function between Ppt1 and Ppt2 since they resulted in the same 
phenotype. Since it is know that Ppt1 and PPT1 perform the same function, Ppt2 and 
PPT2 are structurally similar, and that the phenotype of Ppt1 knock-down and Ppt2 
knock-down is very similar, it may be concluded that PPT2 may also play a role in INCL.  
 In terms of the locomotor evaluation, this study shows that the defects seen during 
embryogenesis may result in motor differences. While it remains to be identified whether 
or not these differences are defects in motor ability, there seems to be an abnormal motor 
phenotype in Ppt1 knock-down larvae. As was said before, the data points have large 
standard errors, but this may reflect the range of effects Ppt1 knock-down had on 
     31
embryos. It could be argued that these differences are not significant since the mutant 
strain did not have significant differences at all developmental stages, but synaptic 
plasticity may have accounted for some compensatory mechanism for movement. 
Furthermore, it could be possible that mutants with severe larval defects never progressed 
to a larval stage and thus, the only larvae experimented with in this study were those with 
more mild neural abnormalities.  
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FUTURE WORK 
 This research is a preliminary investigation into RNAi  knock-down of the Ppt1 
and Ppt2 genes. Now that it has been established that there is a phenotype worth 
exploring, the next step will be to examine the use of different antibody staining markers 
to investigate how different parts of the central nervous system of these Drosophila 
embryos is affected by Ppt1 and Ppt2 RNAi knock-down. Furthermore, 1459 and 1458 
embryos need to be collected in order to act as a control for the Ppt2 knock-down data in 
this experiment.  
 Another area of this research worth exploring is the verification of RNAi knock-
down using Q-PCR and reverse transcriptase PCR. In this way, the amount of RNAi 
knock-down that is actually occurring in these crosses can be quantified. Additionally, 
the research of other genes besides Ppt1 might offer better understanding of how INCL 
functions. The examination of the gene Spinster, a potential Ppt1 interacting gene, might 
provide information about how Ppt1 works in tandem with other genes (22). Finally, the 
analysis of Ppt2 knock-down larvae in the locomotor tests in this experiment would shed 
light on the behavioral effects of Ppt2 knock-down.  
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The Batten Disease Palmitoyl Protein Thioesterase 1
Gene Regulates Neural Specification and Axon
Connectivity during Drosophila Embryonic Development
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Abstract
Palmitoyl Protein Thioesterase 1 (PPT1) is an essential lysosomal protein in the mammalian nervous system whereby defects
result in a fatal pediatric disease called Infantile Neuronal Ceroids Lipofuscinosis (INCL). Flies bearing mutations in the
Drosophila ortholog Ppt1 exhibit phenotypes similar to the human disease: accumulation of autofluorescence deposits and
shortened adult lifespan. Since INCL patients die as young children, early developmental neural defects due to the loss of
PPT1 are postulated but have yet to be elucidated. Here we show that Drosophila Ppt1 is required during embryonic neural
development. Ppt1 embryos display numerous neural defects ranging from abnormal cell fate specification in a number of
identified precursor lineages in the CNS, missing and disorganized neurons, faulty motoneuronal axon trajectory, and
discontinuous, misaligned, and incorrect midline crossings of the longitudinal axon bundles of the ventral nerve cord.
Defects in the PNS include a decreased number of sensory neurons, disorganized chordotonal neural clusters, and
abnormally shaped neurons with aberrant dendritic projections. These results indicate that Ppt1 is essential for proper
neuronal cell fates and organization; and to establish the local environment for proper axon guidance and fasciculation.
Ppt1 function is well conserved from humans to flies; thus the INCL pathologies may be due, in part, to the accumulation of
various embryonic neural defects similar to that of Drosophila. These findings may be relevant for understanding the
developmental origin of neural deficiencies in INCL.
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Introduction
Infantile Neuronal Ceroids Lipofuscinoses (INCL) belongs to a
group of lysosomal storage disorders characterized by the fatal
progressive deterioration of the visual and central nervous system,
and the accumulation of abnormal autofluorescent storage
materials in the brain [1,2]. INCL, the most severe form, results
from defects in the protein Palmitoyl Protein Thioesterase 1
(PPT1) which encodes a lysosomal thioesterase that cleaves long
fatty acids-most likely palmitate-attached to the cysteine residues
of S-acylated protein substrates [3,4]. In mammals, PPT1
expression is found in all cell types at varying quantities with the
highest levels in the brain, eye, and spleen [5,6]. In addition to
being found in lysosomal compartments of neurons, the protein is
also expressed in the pre-synaptic compartments [7,8,9].
Although ubiquitously expressed, PPT1 deficiency affects only
the development and maintenance of cortical neurons in the
nervous system. Afflicted children are normal at birth; but exhibit
progressive cognitive and motor deficits, seizures, and ocular
deterioration and eventual blindness by the age of 3; after which
INCL children remain in a vegetative state until death in their
teens. Microarray studies reveal that changes in gene expression
can be detected at 10 week-old post-natal PPT1 knock-out mice
brains, a time prior to neurodegenerative symptoms [10]. These
findings suggest that the loss of this protein may have embryonic
developmental consequences prior to being symptomatic. If PPT1
does have a role during embryonic neurogenesis, then the
elucidation of the fundamental cellular pathways requiring PPT1
during development will be critical.
Using Drosophila, we investigate the role of PPT1 during the
development of the embryonic nervous system. Previous studies
indicated that the removal of the Drosophila ortholog Ppt1 results in
phenotypes similar to human INCL [11,12]. Ppt1 loss-of-function
(LOF) flies lacking Ppt1 enzymatic activity display some aspects of
INCL disease: reduced life expectancy and an age-dependent
accumulation of autofluorescent storage material in the adult
CNS. Overexpression of Ppt1 in the larval visual system leads to
increased cell death [13]. A dominant gain-of-function modifier
screen for genes interacting with Ppt1 suggests that it has a role in
synaptic developmental pathways and the regulation of synaptic
vesicle endocytosis [14].
Here, we investigate the potential role of Ppt1 during the
generation of the nervous system by focusing on discreet identified
neuronal cell lineages. We hypothesize that while Ppt1 mutants
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may not show detectable adult brain abnormality, early defects at
the cellular level may be present in the form of altered cell fate
specification, proliferation, and axon guidance and connectivity.
Our results support this hypothesis and indicate that the loss of
Ppt1 has consequences much earlier than previously described.
Ppt1 defects lead to mis-specification of identified CNS and PNS
neural precursor cell fates, an abnormal complement of neural
precursors and neurons, and motoneuronal axonal misrouting and
overall defective axon pathfinding and fasciculation. These Ppt1-
associated embryonic phenotypes may contribute to the shortened
lifespan of Ppt1-deficient flies. These findings in Drosophila may be
relevant in identifying the earliest developmental neural defects in
INCL afflicted individuals and potential cellular targets for
therapeutic interventions.
Results
Drosophila Ppt1 RNA and protein are expressed at very
low/undetectable levels
To ascertain the endogenous RNA Ppt1 expression pattern
during development, whole mount in situ experiments on various
developmentally staged embryos (from 0 hr. to 16 hr), and wing,
leg, and eye imaginal discs using digoxygenin-labeled DNA and
RNA Ppt1 probes were performed. Both labeled probes reveal low
ubiquitous staining indicating that Ppt1 RNA is expressed
ubiquitously at a very low level (Figure S1 of Supporting
Information). These results support the hypothesis that Ppt1 acts
as a metabolic enzyme with housekeeping function with relatively
little need for high RNA concentration and/or turnover.
To examine localization of Ppt1 protein, four chicken/rabbit
polyclonal antibodies were generated against different regions of
Ppt1 that include both internal sequences and the C-terminus.
Embryonic, third-instar larvae, and whole adult male and female
lysates were used on Western blot to test all crude sera and affinity-
purified polyclonal antibodies. Results reveal that the endogenous
Ppt1 protein is undetectable under standard conditions (Figure
S2). To determine whether the Ppt1 polyclonal sera is specific to
Ppt1, Western blot using concentrated S2 Schneider cell lysates,
and adult fly head lysates (obtained via a collaboration with Dr.
Robert Glaser of Wadsworth Center of NYS Department of
Health) isolated from over-expressing UAS:Ppt1;P{GAL4-elav.L}
flies were performed. Results indicate that only when Ppt1 is over-
expressed at a high level (greater than 10 folds), or is highly
enriched in S2 lysates, can a band be detected at the expected size
of approximately 28 kD (Figure S2). Since Ppt1 has several
conserved glycosylation sites, de-glycosylation experiment using
PGNAse F (Invitrogen, Inc.) was carried out to confirm the
specificity of the Ppt1 polyclonal sera. Western blot reveals a single
band of ,28kD being shifted to a de-glycosylated band of 26 kD
which is similar in size as the mammalian PPT1 (Figure S2;
Verkruyse and Hoffmann, 1996). Since Ppt1 protein is only
detected when over-expressed on a Western, it indicates that (1)
the polyclonal antibodies were successful at detecting endogenous
Ppt1 protein; and (2) the protein is expressed at very low levels
endogeneously.
To investigate whether the loss of Ppt1 have consequences
during embryonic development, embryos homozygous for three
Ppt1 mutant strains were used: the Ppt1 null allele Df(1)446-20,
which removes Ppt1 and three neighboring genes [11]; and two
EMS-generated alleles: Ppt1A179T which contains a point mutation
that changed alanine 179 to threonine; and Ppt1S77F which
contains a point mutation that changed serine 77 to phenylalanine
[12]. Both EMS alleles exhibit no detectable Ppt1-specific enzyme
activity. Additionally, female embryos trans-heterozygous for
Df(1)446-20 and each point mutant alleles were generated in all
pair-wise combinations: Ppt1A179T/Df(1)446-20, Ppt1S77F/
Df(1)446-20, Ppt1A179T/Ppt1S77F. We compared neural develop-
ment of these embryos to those that are heterozygous for each
Ppt1 strains, namely Df(1)446-20/+, Ppt1A179T/+, and Ppt1S77F/+.
Ppt1-deficient embryos do not display autofluorescence
accumulation
INCL human patients and Ppt1 LOF flies exhibit accumulation
of autofluorescent deposits in adult brains due to the loss of protein
function. Previous studies indicated that adult Ppt1 mutant fly
brains exhibit larger, more abundant autofluorescent deposits than
wild type and this accumulation is visible several days after
pupation [12]. We also examined 14-day old wild type and Ppt1
LOF S77F adult fly brains for differences in autofluorescent
deposits. As in the previous studies, our results showed that there is
detectable difference in the levels of autofluorescent deposits.
Although wild type adult brains display minimal deposits, Ppt1
LOF brains had more deposits visible at various wavelengths. We
asked whether these accumulations are detectable during embryo-
genesis. Wild type and Ppt1 LOF stage 8–17 embryos were
examined for increased autofluorescent deposits in the developing
nervous system. We detected no difference in the level of
autofluorescence between wild type and Ppt1embryos at all stages
examined (data not shown) indicating that the accumulation of
abnormal storage materials is age-dependent and that the duration
of embryogenesis is not sufficient for build-up to occur.
Ppt1 mutants display aberrant cell fate specification in
early embryonic CNS development
We addressed the question of whether Ppt1 is involved in the
early events of neurogenesis- namely neural precursor specification
and division. We focused on the development of some of the most
well characterized neural cell lineages in the fly CNS using the
mAb EVE (mAb 2B8). EVE has a defined expression patterns in
ganglion mother cells (GMC) and daughter neurons of identified
neural precursor lineages NB1-1, 3-3, 4-2, and 7-1 [15,16,17,18].
EVE is expressed in the first-born precursor of NB1-1, GMC1-1a,
and its progeny, the aCC and pCC motoneurons; the EL neurons
deriving from NB3-3; GMC4-2 and its daughter neurons RP2
motoneuron and its sib from NB4-2, and the U/CQ neurons
deriving from NB7-1.
Results indicate that Ppt1 mutant embryos display abnormal
complement of EVE+ GMCs and their progeny in many
hemisegments, as early as stage 11/12 of embryogenesis. At stage
11–12, EVE is expressed in GMCs that produce the RP2
motoneuron and its sib; aCC/pCC and U/CQ neurons
(Figure 1A). Ppt1 mutant embryos from Df(1)446-20, Ppt1A179T,
and Ppt1S77F, and trans-heterozygous Ppt1 mutant crosses show a
variety of phenotypes. Some embryos display cellular disorgani-
zation where EVE+ GMCs are displaced. In others, there is a loss
or gain of extra EVE-positive GMCs and neurons in many
hemisegments (Figure 1B–E). The most prevalent phenotype is the
loss of GMC4-2.a, the parental precursor that will give rise to the
RP2 motoneuron. Occasionally, extra U/CQ and aCC/pCC
GMCs are also observed as also the presence of extra RP2s or its
sib after GMC4-2.a has divided (Figure 1D–E). Overall, 31%
(n= 42) of Ppt1- embryos display abnormality at stage 12. Later in
embryonic development during stage 14–15 when the EVE+
GMCs give rise to EVE+ neurons, the loss of EVE+ RP2s is
observed in a small, but significant percentage of hemisegments in
Ppt1mutants (Figure 2; Table 1). Specifically, over 36% of T1-A8
hemisegments show a loss of RP2s in Df(1)446-20 embryos. Point
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mutants and trans-heterozygous embryos show 12–17% loss in all
hemisegments (Table 1). The degree of penetrance of this EVE
neural phenotype is variable: all Df(1)446-20 embryos show at
least two missing RP2s whereas Ppt1A179T and Ppt1S77F point
mutations range from 32–50%. 63% of embryos from
Ppt1A179T6Df(1)446-20 trans-heterozygous crosses and 27% of
Ppt1S77F6Df(1)446-20 trans-heterozygous crosses display a partial
loss of EVE+ RP2 neurons (Figure 2; Table 2). In contrast, all Ppt1
mutant strains outcrossed to wild type Oregon-R, Df(1)446-20/+,
Ppt1A179T/+, and Ppt1S77F/+, all showed normal EVE expression
(Tables 1 and 2). These results indicate that the EVE phenotypes
are due to the loss of Ppt1.
Figure 1. Ppt1 LOF mutants exhibit abnormal complement of EVE+ neural precursors and neurons. (A) In wild type, EVE is expressed in
GMC4-2.a, the neural precursor that give rise to RP2 motoneuron and its sib (arrow); and in a cluster of GMCs that give rise to the aCC, pCC, CQ
neurons (arrowhead). (B–E) In Ppt1 mutants, many hemisegments exhibit a variety of phenotype including the loss of GMC4.2a (arrow in B and E),
extra RP2/sib neurons (arrowhead in D), disorganized EVE+ clusters (C), and extra aCC/pCC cells (arrowhead in E). In all panels, embryos are at S11–12
of development; anterior, up; caret, midline.
doi:10.1371/journal.pone.0014402.g001
Figure 2. Loss of Ppt1 results in missing EVE+ RP2 neurons in many hemisegments of S16 embryonic CNS. Arrowhead indicates RP2
neuron in all panels. (A). Wild type EVE+ CNS pattern. (B–E) Ppt1 LOF mutants exhibit a variety of phenotype including the loss of EVE+ RP2s in some
hemisegments (red arrowhead in B–E), disorganized or missing aCC/pCC clusters (white arrowhead in B, D and E). Anterior, up; caret, midline.
doi:10.1371/journal.pone.0014402.g002
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EVE is also essential for normal axonal guidance and
innervation of the RP2 motoneuron [19] thus EVE can provide
clues as to whether the observed alterations in cell fate lead to
faulty axon pathfinding and innervation. To verify the mis-
specification of neuronal cell fates in the EVE+ lineages as well as
to assess the RP2 axonal projections, Df(1)446-20 and Ppt1A179T
flies were crossed to lines bearing either the UAS-tau-LacZ or UAS-
CD8-GFP reporter (RN2-Gal4:UAS-CD8-GFP or RN2-GAL4:UAS-
tau-LacZ) driven by the RP2/aCC/pCC-specific Gal4 driver (RN2-
Gal4) to clearly mark the cell bodies and axons of aCC and pCC,
and RP2 neurons [20]. Anti- b-gal staining and GFP visualization
of embryos from these crosses confirmed EVE staining results.
Ppt1;RN2-Gal4:UAS-CD8-GFP and Ppt1; RN2-Gal4:UAS-tauLacZ
embryos display a loss of either tauLacZ or GFP-expressing
RP2s and aCC/pCC neurons in many hemisegments; and
disorganized cellular arrangements of the remaining LacZ-positive
neurons. In many Ppt1 mutants, the remaining RP2 motoneuron
exhibits abnormal axon trajectory (Figure 3). Normally at late
embryogenesis, the RP2 motoneuron extends its axon anteriorly
toward the ipsilateral neighboring anterior segment to join the
intersegmental nerve (ISN) to exit the CNS and eventually
synapsing onto the dorsal muscle (Figure 3A). In many Ppt1A179T;
UAS-tauLacZ embryos, the RP2 neurons extend its axons in the
wrong direction-posteriorly to join the posterior ipsilateral ISN
instead (Figure 3D) while other RP2 axons project contralaterally
toward the midline, stalled, and never exit the CNS (Figure 3E).
These embryos also display a loss of either aCC or pCC neurons
in many hemisegments (Figure 3B–E). Collectively, these studies
indicated that the loss of Ppt1 caused abnormal neuronal cell fate
specification and defective axon pathfinding.
Embryonic glial development is normal in Ppt1 mutants
Since neuronal and glial development are temporally and
spatially linked and can be derived from a common neuronal
precursor (e.g. NB1-1 produces both aCC/pCC neurons as well as
the A and B glia located dorsally on the CNS [21] ), glial
development was examined using the glial-specific marker REPO
(mAb 8D12). The evolutionary conserved REPO protein is
expressed in most glia in the embryonic CNS and PNS. During
embryogenesis, REPO is essential for the migration and
differentiation of glia, particularly the longitudinal glia of the
CNS and the exit glia of the PNS. All Ppt1 LOF mutants exhibit
normal REPO-positive glia; thus Ppt1 is not essential for the
specification of embryonic glia (data not shown).
Ppt1 mutants exhibit variable embryonic CNS and PNS
axonal defects
Overall axon guidance and fasciculation during neural
development were examined using a number of axonal markers,
BP102, FUTSCH (mAb22C10), and Fasciclin II (mAb1D4). In
wild type, the axon tracts of the embryonic CNS consist of two
longitudinal axon bundles running lengthwise along the ventral
nerve cord intersected by segmentally reiterated pairs of anterior
and posterior commissures that crosses the midline at every
segment (Figure 4A). The CNS axon scaffold can be visualized
using BP102 which recognizes a carbohydrate epitope present on
all CNS axons [22]. 73% of Df(1)446-20, 35% of Ppt1A179T, and
24% of Ppt1S77F embryos show mild to severe defects (Figure 4;
Table 3). Mild defects include irregularly spacing of the ventral
nerve cord, some disorganization of the axon scaffold, abnormally
thin or thick, and wavy longitudinal connectives. Moderate defects
include narrowing of spaces between the commissures (Figure 4B),
broader and/or more compressed anterior and posterior commis-
sures, and interrupted, frayed longitudinal connectives (Figure 4C).
Severe defects observed include severe disorganization of the
longitudinal tracts at many segments, the complete loss of
longitudinal connectives in other segments, and fused or missing
commissures (Figure 4C & D).
To evaluate the morphology of a more discrete subset of axonal
longitudinal connectives, Df(1)446-20, Ppt1A179T, and Ppt1S77F, and
trans-heterozygous Ppt1 mutant embryos were stained with
mAb1D4. At stage 17, mAb1D4 recognizes the neural adhesion
protein Fasciclin II, which is expressed in three discrete axon
longitudinal bundles on either side of the midline (Figure 5A; [23]).
50–58% of Ppt1 mutant embryos display abnormal FasII-positive
longitudinal connectives ranging from mild to severe (Table 3).
Mild defects include loose and defasciculated connectives, wavy in
appearance. More severe FasII defects include ectopic midline
crossing of the longitudinal connectives, discontinuous connectives
in all three FasII bundles, and frayed connectives due to
defasciculation (Figure 5B).
We examine the specific requirement of Ppt1 in neurons by
driving the expression of Ppt1-RNAi in strains containing the ds
RNA-GD3286 construct (obtained from the Vienna Drosophila
RNAi Center [24]); and the dsRNA-JF01972 construct from the
TriP-1 collection (Bloomington Drosophila Stock Center) using
various neural-specific Gal4 drivers (Bloomington Drosophila
Table 1. Percentage of hemisegments in Ppt1-deficient
embryos with missing EVE+ RP2 neurons.
genotype % n
wild type 0 220
Ppt1Df(1)446-20 36.4 220
Ppt1Df(1)446-20/+ 0 220
Ppt1A179T 16 198
Ppt1A179T/+ 0 220
Ppt1S77F 17 198
Ppt1S77F/+ 0 220
Ppt1S77F/Ppt1Df(1)446-20 12 220
Ppt1A179T/Ppt1Df(1)446-20 12 374
n, number of hemisegments at stage 14–16.
doi:10.1371/journal.pone.0014402.t001
Table 2. Penetrance of EVE+ RP2 phenotype in Ppt1-
embryos.
genotype % n
wild type 0 30
Ppt1Df(1)446-20 100 25
Ppt1Df(1)446-20/+ 0 10
Ppt1A179T 50 18
Ppt1A179T/+ 0 10
Ppt1S77F 32 28
Ppt1S77F/+ 0 10
Ppt1S77F/Ppt1Df(1)446-20 27 37
Ppt1A179T/Ppt1Df(1)446-20 63 24
%, percentage of stage 15–16 embryos with 2 or more missing RP2s.
n, number of embryos scored.
doi:10.1371/journal.pone.0014402.t002
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Stock Center). The dsRNA-GD3286 construct recognizes 310
nucleotides within the first exon of the Ppt1 gene; the dsRNA-
JF01972 construct recognizes 531 nucleotides-nearly all the first
exon of the gene. Ppt1-RNAi embryos were examined for Ppt1-
associated FasII defects. 85–100% Ppt1RNAi-elav-Gal4 embryos
display defects ranging from mild to severe axon bundles
(Figure 5C and D; Table 4). Similarly, 85% of Ppt1RNAi- U/
CQ-Gal4 and 93% Ppt1RNAi-aCC/RP2-Gal4 embryos exhibit
varying degrees of axon defects ranging from wavy but intact
bundles; to frayed, discontinuous or missing bundles in many
hemisegments. In contrast, embryos from the parental strains
exhibit normal axon patterns (Table 5). These results collectively
indicate that Ppt1 is essential in the neurons for proper axon
guidance and fasciculation.
The developing PNS of Ppt1mutants also show neuronal defects
as assayed by 22C10, an antibody that recognizes the cytoskeletal
FUTSCH protein found in the cytoplasm of a subset of CNS and
PNS neurons and axons as well as their projections [25].
Normally, FUTSCH is expressed in the cell bodies as well as
the axons and dendrites of 44 PNS neurons per abdominal
segment [26]. 22C10-positive PNS neurons include the dorsal
cluster (d), the ventral and ventral’ cluster (v and v9), and the
lateral cluster which consists of five chordotonal organs (lch5).
Wild type and Ppt1 LOF embryos showed no detectable difference
in the number of neurons or axon projections in the l, v, and v9
neuron clusters. However, the lch5 neurons showed a variety of
defects including decreased number of sensory neurons, fused and
abnormally shaped neurons, and disorganized clusters with
aberrant dendritic projections (Figure 6; Table 5). Occasionally,
fasciculation defects with abnormal axonal connections between v9
clusters and ISN are observed (data not shown). These findings
indicate that lch5 neuron clusters are preferentially more sensitive
than l, v, and v9 clusters to the loss of Ppt1.
Discussion
RNA and antibody expression results reveal the low abundance
nature of Ppt1 RNA and protein confirming what was previous
thought- Ppt1 is an essential housekeeping gene. Because of its low
abundance, we are unable to ascertain the subcellular localization
of Ppt1 and thus could not determine whether fly Ppt1 is
lysosomal, synaptic, or both. To address this question, Ppt1 would
need to be over-expressed by at least 17-folds to be at a marginally
detectable level using immunofluorescence. This is not ideal since
Ppt1 over-expression leads to apoptosis. Our studies clearly
indicate that Ppt1 protein is expressed ubiquitously at a very low
level such that only a minute amount is required for function.
Whether this minute amount of protein resides predominantly in
Figure 3. Ppt1 mutants exhibit abnormal RP2 axon trajectories. S16 ventral nerve cord stained with anti-b-gal to detect RN2-tau-lacZ
expressed in aCC, pCC and RP2 neurons. (A) Wild type RN2-tau-lacZ pattern showing RP2 neuron and its axon trajectory (white arrow); and aCC/pCC
neurons (arrowhead). (B–D). Ppt1A179T; RN2-Gal4:UAS-tauLacZ embryos display a loss of RP2 motoneurons (asterisks) and aCC/pCC neurons
(arrowheads) in many hemisegments; and disorganized cellular arrangements of the remaining LacZ-positive neurons. Many hemisegments have
normal RP2 axon trajectory (white arrow) while others do not (black arrow). The RP2 in panel C shows an abnormal axon trajectory projecting
posteriorly instead of anteriorly. Panel E is an enlarged subset of B. Anterior, up; caret, midline.
doi:10.1371/journal.pone.0014402.g003
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the lysosomes and/or synapses for the turnover of palmitoylated
developmental proteins, it is necessary and its absence would most
likely have similar consequences.
Our results indicate that Ppt1 is essential at a time when neural
precursors are being determined, one of the earliest stages of
embryonic neural development. Small discreet defects were
detected early shortly after gastrulation with the alteration in
CNS neural precursor cell fates in a number of identified neural
precursors. Specifically, the phenotype is limited to a discreet
subset of EVE+ neural lineages (e.g. the neuroblast lineage giving
rise to RP2s, aCC and pCC neurons); while other EVE+ cells such
as U’s and EL interneurons are normal. In the affected lineages,
the loss of Ppt1 has small consequences at the early cell
determination stage such that only a subset of all EVE+ RP2s,
aCC/pCC neurons are affected. This indicates that even at this
very early stage of neurogenesis, Ppt1-mediated protein turnover is
essential. Neural defects increase as development proceeds such
that by mid-to–late embryogenesis, malformed neurons and
abnormal longitudinal axon tracts are visible in nearly all Ppt1-
deficient embryos. Specifically, the development of the RP2, aCC
and pCC neurons requires Ppt1; most likely through regulating
EVE expression. Without Ppt1, many RP2, aCC/pCC neurons
are abnormally positioned or missing; while some exhibit aberrant
axon projections. Since EVE regulates proper axon projections in
the developing CNS, particularly dorsally projecting aCC and
RP2 motoneurons (pCC is an interneuron), this phenotype is
wholly unexpected. These pathfinding and fasciculation defects
reflect what we suspect: Ppt1-mediated turnover of palmitoylated
developmental proteins is necessary throughout development such
that its loss is cumulative and progressive. This is supported by
previous studies showing that young adult brains exhibit age-
dependent abnormal autofluorescence deposits due to the absence
of Ppt1 [12]. Neurons, in particular, exhibit a high rate of
palmitoylation-depalmitoylation dynamics due to its high level of
signal transduction and protein trafficking through neurotrans-
mitter release. Since there are numerous endosomal/lysosomal
pathways, the loss of one protein would not necessarily result in
massive disturbances but may limit the number of protein
turnovers and recycling which may cause a ‘‘domino’’ effect by
directly or indirectly disrupting downstream pathways during
neural development.
Downstream targets of Ppt1 during neurogenesis are largely
unknown. A previous study indicates that FasII, a neural
adhesion protein, may be a candidate [14]. Ppt1 over-expression
screens have isolated FasII as a potential Ppt1-interacting protein.
Our results showed that Ppt1-deficient embryos display FasII-
specific axon fasciculation defects. FasII, a homolog of the
vertebrate NCAM, is a palmitoylated protein and serves as a
second anchor for proteins involved in N-CAM mediated
signaling at the membrane [27]. Fasll has also been shown to
interact with lipid rafts to mediate FGF signaling to promote
neurite outgrowth [28]. Perhaps Fasll plays a similar role during
Table 3. Percentage of Ppt1-deficient embryos displaying
axonal defects.
Antibody staining Wild type Df(1)446-20 Ppt1A179T Ppt1S77F
anti-BP102 0% (6) 73% (34) 35% (34) 12% (49)
anti-fasII (1D4) 0% (11) 58% (36) 50% (46) n/d
Anti-FUTSCH (22C10) 0% (10) 70% (50) 60.5% (38) n/d
Parentheses, the number of stage 16–17 embryos assayed.
n/d: not determined.
doi:10.1371/journal.pone.0014402.t003
Figure 4. CNS scaffold abnormalities in Ppt1 mutant embryos. In all panels, S16 embryos were stained with BP102. (A) Wild type embryo. (B)
Axon defects range from mild phenotypes such as irregularly spaced axon tracts in commissures and wavy, thinning longitudinal connectives; to
more severe phenotype such as fused commissures and disorganized CNS tracts (C and D). Anterior, up.
doi:10.1371/journal.pone.0014402.g004
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fly neurogenesis where it is involved in lipid raft-mediated
signaling. Since Ppt1 has been suggested to also facilitate cell
signaling via its localization to lipid rafts [29], FasII may require
Ppt1-mediated palmitoylation turnover at the membrane to
regulate the integration of signaling required to insure proper
axon outgrowth and fasciculation.
The loss of Ppt1 has varied consequences from the loss or gain of
neurons, axon fasciculation defects, to axon guidance in a subset of
motor neurons (e.g. RP2, aCC), sensory neurons, and interneurons
(e.g. pCC but not the EL interneurons). This observation is
analogous to what is observed in INCL humans and animal
models. INCL patients undergo progressive degeneration in
selective areas of the brain while leaving others intact. PPT1-
deficient adult mice exhibit the loss of GABAergic interneurons in
discrete regions of the brain [10] and thalamic neurons [30]
months prior to being symptomatic. It is presently unclear whether
PPT1-deficiencies affect mice earlier, during embryonic neural
development.
The low penetrance of Ppt1 phenotype indicates that the loss of
Ppt1 is generally well tolerated perhaps due to the presence of
compensatory mechanisms. A closely related sister gene, PPT2,
exists in mammals [31] and in Drosophila. PPT2 knock-out mice
display many of the same INCL phenotype and pathology
including spasticity and autofluorescence accumulation in the
brain [32]. We are currently investigating whether the PPT2 fly
homolog, Ppt2, also have an embryonic neural phenotype and
whether Ppt1/Ppt2 double mutants have a more severe phenotype
than the single mutation.
Materials and Methods
Drosophila Strains
Ppt1 LOF mutant alleles Ppt1A179T, Ppt1S77F, and the Df(1)446-
20 deficiency line were provided by Dr. Robert Glaser (Wads-
worth Center, NYS Department of Health, Albany, NY). Oregon-
R, w*; P{RN2-GAL4}P, P{UAS-tau-lacZ.B}2 and w*; P{RN2-
GAL4}P, P{UAS-mCD8::GFP.L}LL5 , Elav-Gal4 driver, U/CQ-
Gal4 driver, aCC/RP2-Gal4 driver, and Ppt1-RNAi TRiP line,
and Oregon-R were obtained from Bloomington Drosophila Stock
Center. Ppt1- UAS RNAi flies (w1118; P{GD3286} [14]) was
obtained from Vienna Drosophila RNAi Center (Vienna, Austria).
All strains were maintained on standard Drosophila cornmeal-yeast
medium at 25uC.
To detect autofluorescence deposits, brains from 14-day old
Oregon-R and Ppt1S77F were extracted and immediately examined
on a Leica SP2 confocal microscope for comparison.
Figure 5. Mutant Ppt1 and Ppt1 RNAi knock-down in neurons result in defective axon tracts in the developing CNS. In all panels, S17
embryos were stained with 1D4 antibody. (A) FASII is expressed in three longitudinal connectives at this stage. (B) Ppt1A179T embryos exhibit
discontinuous and frayed longitudinal connectives. (C, D) Ppt1 RNAi expression under the control of elav gal4 driver results in a range of axon
guidance phenotype including wavy bundles with some faulty axon crossing over the midline (arrow in C); and disorganized and/or broken
connectives, and fused commissures (arrows in D). Anterior, up.
doi:10.1371/journal.pone.0014402.g005
Table 4. Quantitation of Ppt1 RNAi embryos displaying FasII
defects.
genotype % defective
Ppt15499RNAi 0.03 (30)
Ppt125952TRiP RNAi 0 (30)
elav-gal4 0 (33)
UAS tauLacZ CQ2-gal4 0 (30)
UAS tauLacZ RN2-gal4 0 (35)
Ppt15499RNAi6elav-gal4 100 (81)
Ppt125952TRiP RNAi6elav-gal4 85.7 (42)
Ppt15499RNAi6UAS tauLacZ CQ2-gal4 85 (67)
Ppt15499RNAi6UAS tauLacZ RN2-gal4 93.4 (106)
Parentheses, the number of stage 16–17 embryos assayed.
Ppt1 RNAi expression is driven by the following neural specific Gal4 drivers:
elav-gal4-drives expression in CNS and PNS neurons.
UAS tau-LacZ CQ2-gal 4 driver- drives tau-LacZ expression in U/CQ neurons.
UAS tau-LacZ RN2-gal 4 driver- drives tau-LacZ expression in aCC and RP2
neurons.
doi:10.1371/journal.pone.0014402.t004
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Table 5. Quantitation of Ppt1 axon defects in the embryonic CNS and PNS.
phenotype Wild type Ppt1A179T Ppt1446-20
Ppt15499RNAi6
elav-gal4
Ppt125952TRiP
RNAi6elav-gal4
Ppt15499RNAi6UAS
tauLacZ CQ2-gal4
Ppt15499RNAi6UAS
tauLacZ RN2-gal4
PNS
Irregular spacing of
lch5 neuron clusters
0 6 6 n/d n/d n/d n/d
Missing lch5 neurons 0 4 6 n/d n/d n/d n/d
Malformed lch5
neurons
0 13 13 n/d n/d n/d n/d
CNS
slightly irregular and/
or wavy longitudinal
tracts
0 31 21 40 9 25 7
Discontinuous, frayed
longitudinal tracts
0 8 11 35 33 35 99
Irregular, missing or
fused commissures
0 16 17 6 14 7 10
Total number of
embryos scored
27 69 58 81 42 67 106
-number of embryos of each genotype displaying various fasII and 22C10 defects; many embryos exhibit combination of phenotypes.
n/d: not determined.
doi:10.1371/journal.pone.0014402.t005
Figure 6. Chordotonal neurons (lch5) in the developing PNS are abnormal in many Ppt1 LOF embryos. In all panels, lch5 neurons are
indicated by the arrows. Side view of S17 embryos stained with Mab 22C10. (A) Wild type clusters of lch5, v, and v9 neurons are located in every
abdominal segment. (B–E) lch5 neurons in mutant Ppt1 embryos demonstrate a variety of defects: decreased number of neurons (B), fused and
abnormally shaped (D, E), organization and positional defects, and thin axon bundles (black arrowhead) (B and C). dorsal, up.
doi:10.1371/journal.pone.0014402.g006
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Immunocytochemistry and Immunofluorescence
Embryos were fixed and stained according to previously
described methods [33,34], and using the following primary
antibodies obtained from University of Iowa Developmental
Studies Hybridoma Bank: mAb 22C10 (1:50), mAb BP102
(1:50), mAb 2B8 (1:30), and mAb 1D4 (1:5). b-gal monoclonal
antibody at 1:1000 obtained from Jackson ImmunoResearch, Inc.
Immunocytochemical detection was performed using HRP-
conjugated goat anti-mouse secondary antibody (1:300; Jackson
ImmunoResearch, Inc.). Immunofluorescence was performed
using Alexa-488 and Alexa-594 conjugated goat anti-mouse
secondary antibodies (1:300; Molecular Probes/ Invitrogen,
Inc.). For each genotypic staining of EVE, 100–200 thoracic and
abdominal hemisegments from at least 20 appropriately staged
embryos were counted. Digital images of stained embryos were
captured using either the Advanced Color SPOT system or the
Retiga EXi Fast 1394 mounted onto a Nikon E600 compound
microscope.
Supporting Information
Figure S1 Whole mount in situ RNA hybridization reveals that
Ppt1 transcript is ubiquituously expressed at low levels during (A)
embryogenesis and (B) 3rd instar imaginal discs. 0–16 hours wild
type embryos and 3rd instar imaginal discs were collected, fixed
and hybridized with digoxygenin-labeled anti-sense Ppt1 RNA
probes. Anti-sense RNA probes were generated from a CG12108
cDNA clone GM21019 (Research Genetics). Embryo in situ
hybridization was performed using standard protocols.
Found at: doi:10.1371/journal.pone.0014402.s001 (0.82 MB
PDF)
Figure S2 Western blot using affinity-purified Ppt1 polyclonal
antibody (generated against the C-terminus) of S2 cell lysate, wild
type W1118 fly head extract (arrows), and over-expressed Gal4-
UAS-Ppt1 head extract untreated (A) and treated with pGNAse
(B) to remove N-glycosylation. Results indicate that although no
band is detected in the S2 lysate and W1118 lanes (arrows), Ppt1
antibody is specific to Ppt1 protein and can be detected when Ppt1
is over-expressed (A and B). Two rabbit and two chicken
polyclonal antibodies were generated using the following peptides
located in the internal region of the Ppt1 gene: VAERCP-
NPPMRNLIT, ATYWHDPIMENKYR, and IVQPKESQWF-
QYYTT ; and VYQNLGLDKMHRQGQ located at the C-
terminal region (GeneMed Synthesis, Inc.; Aves Laboratories,
Inc.). Affinity purifications were performed using the Pierce
Biotechnology SulfoLink (#20405) and AminoLink kit (#44890)
according manufacturer’s standard protocols. Western blot was
performed using the ECL Western Blotting Analysis System
(Pierce Biotechnology). Deglycosylation experiments were per-
formed using lysates prepared from S2 Schneider cells, and adult
fly heads from W1118 and UAS:Ppt1 2.1/GMR:GAL4 flies.
Samples were treated with PGNase F according to manufacturer’s
instruction (glycerol free kit #P0705S; New England Biolabs, Inc.)
prior to Western Blotting.
Found at: doi:10.1371/journal.pone.0014402.s002 (0.29 MB
PDF)
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